Galleri volume grows but pricing and competitors pressure margins
- Galleri test volume grew 35% year over year in the second quarter of 2026.
- Screening revenue made up about 95 percent of total revenue in the latest quarter.
- Average selling prices continue to decline as the company shifts toward digital health and lower employer pricing.
- An expected FDA advisory committee meeting this fall is the next major step toward broad Medicare coverage.
- The company closed a $110 million financing deal with Samsung to help expand into Asian markets.
Balancing demand and price
GRAIL is trying to make Galleri a standard cancer screen. The pitch is simple: one blood test that looks for a shared cancer signal across more than 50 cancer types, then points to where that signal may have started. The hard part is proving that this test should be used and paid for broadly.
The bull case centers on steady demand and the path to FDA approval. Galleri sales volume grew 35% year over year in the second quarter of 2026, reaching over 61,000 tests. Management expects an FDA advisory committee meeting in the fall, which sets up a potential approval in early 2027. The company also closed a $110 million financing deal with Samsung, clearing a major regulatory hurdle and funding expansion into Asia.
The bear case highlights weakening unit economics and rising competition. Average selling prices continued to fall in the second quarter due to planned lower employer pricing and a shift toward digital health channels. At the same time, new competitors are launching rival tests, which management noted is causing customer confusion and forcing GRAIL to spend more time educating doctors.
The next year is about proof and cash. Investors need to see average selling prices stabilize and the FDA advisory committee meeting go well. The Medicare MCED law helps the long-term case, but coverage begins in 2029 and still depends on FDA approval and evidence that payors accept.
One test pays the bills
GRAIL makes most of its money by selling the Galleri test in the United States. Galleri is sold today as a Laboratory Developed Test, which means it is offered through a lab pathway rather than as a fully FDA-approved medical device. Customers come through primary care doctors, health systems, self-insured employers, digital health partners, and life insurance providers.
In the second quarter of 2026, screening revenue was about 95 percent of total revenue. That makes the business simple to understand, but also highly concentrated. If Galleri adoption slows, pricing weakens, or regulators and payors push back, there is no large second business to soften the hit.
A smaller development services business serves biopharma and clinical customers using the company methylation platform. That line was about 5 percent of second quarter revenue. GRAIL has cut back spending on other product programs so it can focus on Galleri commercialization and the FDA premarket approval submission.
The long-term money path is reimbursement. Today, GRAIL is building demand before broad Medicare coverage. The Medicare MCED law creates a national coverage process for FDA-approved early detection tests, but the benefit starts in 2029. That timing matters because GRAIL may need more capital if cash burn stays high before coverage arrives.
Galleri, plus smaller options
Galleri
Galleri is the core product and the main revenue driver. It is a blood-based multi-cancer early detection test designed to detect a shared cancer signal across more than 50 cancer types and predict where the signal came from.
Galleri FDA PMA program
The PMA path is not a separate test, but it is central to the value of Galleri. FDA approval is needed for the broad reimbursement plan tied to the Medicare MCED law.
Research-use-only services
GRAIL offers research-use-only services to biopharma partners through its methylation platform. This is much smaller than screening revenue and is part of development services.
Development services
Development services revenue comes from biopharmaceutical and clinical customers. It made up about 5 percent of Q2 2026 revenue.
Diagnostic aid for cancer program
The diagnostic aid for cancer program is not the focus today. GRAIL has substantially decreased investment in this program to direct resources toward Galleri.
Minimal residual disease program
The minimal residual disease program has also been de-prioritized. It may retain future optional value, but the current company story is Galleri.
Revenue mix is concentrated
The segment mix is from the second quarter of 2026. Screening revenue was 95 percent of total revenue, making changes in Galleri volume or price the main driver for the whole company.
What could break the thesis
ASP keeps falling
High impact · High oddsAverage selling prices continue to decline as the company expands digital health volume and offers lower employer pricing. If that pace continues, strong volume growth may not turn into strong margins. Lower pricing could also raise future funding needs before Medicare coverage starts in 2029.
FDA AdCom delays or limits approval
High impact · Medium oddsGRAIL expects an FDA Advisory Committee meeting in the fall of 2026. The committee could raise concerns about the test data or request more evidence, which would delay potential early 2027 approval. A weaker label would limit the commercial upside even if approval arrives.
MCED competition pressures share
Medium impact · High oddsExact Sciences and Guardant Health launched competing early detection products in 2025. Management noted that new tests with aggressive marketing have caused customer confusion. This requires additional sales force education and could pressure Galleri market share.
Clinical utility doubt after NHS result
High impact · Medium oddsThe NHS-Galleri trial showed a reduction in stage 4 cancer diagnoses, but it did not meet the primary endpoint for a statistically significant combined reduction in stage 3 and 4 cancers. That gives payors and regulators a reason to question whether Galleri improves outcomes enough to justify broad use.
In one breath
What does GRAIL do?
GRAIL sells Galleri, a blood test that screens for a cancer signal across more than 50 cancer types. The company is focused on proving Galleri should be widely used and reimbursed.
Is Galleri FDA approved?
Galleri is currently sold in the United States as a Laboratory Developed Test. GRAIL expects an FDA advisory committee meeting in the fall of 2026, and FDA approval is central to the Medicare coverage path.
Why does average selling price matter so much?
Average selling price shows how much GRAIL earns per Galleri test before costs. Volume grew 35% in Q2 2026, but ASP continues to fall, so investors need to know whether growth is coming at the cost of weaker economics.
What is the Medicare MCED law?
The law created a Medicare coverage benefit category for multi-cancer early detection tests. For GRAIL, the key point is that coverage starts in 2029 and depends on FDA approval and CMS review.
